SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-008706
Filing Date
2022-05-10
Accepted
2022-05-10 07:01:40
Documents
75
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q verv-20220331.htm   iXBRL 10-Q 2630964
2 EX-31.1 verv-ex31_1.htm EX-31.1 19007
3 EX-31.2 verv-ex31_2.htm EX-31.2 19135
4 EX-32.1 verv-ex32_1.htm EX-32.1 11496
5 EX-32.2 verv-ex32_2.htm EX-32.2 11468
  Complete submission text file 0000950170-22-008706.txt   8771766

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT verv-20220331_def.xml EX-101.DEF 229042
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT verv-20220331_cal.xml EX-101.CAL 41028
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT verv-20220331_lab.xml EX-101.LAB 474059
9 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT verv-20220331.xsd EX-101.SCH 60707
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT verv-20220331_pre.xml EX-101.PRE 362241
69 EXTRACTED XBRL INSTANCE DOCUMENT verv-20220331_htm.xml XML 1493084
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40489 | Film No.: 22907293
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences